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CLINICAL AND POPULATION SCIENCES
Comparative Effectiveness and Safety of Non–
Vitamin K Antagonist Oral Anticoagulants in Atrial 
Fibrillation Patients
Wengen Zhu , MD; Zi Ye , MD; Shilan Chen, MD; Dexi Wu , MD; Jiangui He, MD; Yugang Dong, MD;  
Gregory Y.H. Lip , MD; Chen Liu , MD
BACKGROUND AND PURPOSE: Several observational studies have compared the effect of the non–vitamin K antagonist oral 
anticoagulants to each other in patients with atrial fibrillation. However, confounding by indication is a major problem when 
comparing non–vitamin K antagonist oral anticoagulant treatments in some of these studies. This meta-analysis was 
conducted to compare the effectiveness and safety between non–vitamin K antagonist oral anticoagulant and non–vitamin 
K antagonist oral anticoagulant by only including the propensity score matching studies.
METHODS: We systematically searched the PubMed and Ovid databases until May 2020 to identify relevant observational 
studies. Hazard ratios (HRs) and 95% CIs of the reported outcomes were collected and then pooled by a random-effects 
model complemented with an inverse variance heterogeneity or quality effects model.
RESULTS: A total of 17 retrospective cohort studies were included in this meta-analysis. Compared with dabigatran use, 
the use of rivaroxaban was significantly associated with increased risks of stroke or systemic embolism (HR, 1.16 [95% 
CI, 1.05–1.29]) and major bleeding (HR, 1.32 [95% CI, 1.24–1.41]), whereas the use of apixaban was associated with a 
reduced risk of major bleeding (HR, 0.78 [95% CI, 0.67–0.90]) but not stroke or systemic embolism (HR, 0.84 [95% CI, 
0.56–1.28]). Compared with rivaroxaban use, the use of apixaban was associated with a decreased risk of major bleeding 
(HR, 0.63 [95% CI, 0.54–0.73]) but not stroke or systemic embolism (HR, 0.83 [95% CI, 0.67–1.04]). Reanalyses with the 
inverse variance heterogeneity or quality effects model produced similar results as the random-effects model.
CONCLUSIONS: Current observational comparisons with propensity score matching methods suggest that apixaban might be a 
better choice compared with dabigatran or rivaroxaban for stroke prevention in atrial fibrillation patients.
Key Words: anticoagulants ◼ apixaban ◼ atrial fibrillation ◼ propensity score ◼ safety
Atrial fibrillation (AF) is the most common arrhyth-mia, and patients with AF are 5-fold more likely to experience a stroke or systemic thromboembolism 
compared with those without AF.1 Oral anticoagulants 
including the non–vitamin K antagonist oral antico-
agulants (NOACs; ie, factor Xa inhibitors [rivaroxaban, 
edoxaban, and apixaban] and direct thrombin inhibitor 
[dabigatran]) and warfarin are effective in preventing AF-
related stroke. Current guidelines recommend treatment 
with NOACs as the standard of care in AF given their 
improved effectiveness and safety effects over warfarin 
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There are still no direct head-to-head randomized clini-
cal trials (RCTs) for comparing effectiveness and safety 
between the different NOAC drugs. In recent years, sev-
eral observational studies have directly compared the 
effectiveness and safety between the NOACs versus 
one another among AF patients, suggesting that apixa-
ban may be a better choice compared with dabigatran or 
rivaroxaban in terms of the lower major bleeding risks.5–9
Confounding by indication is a major problem when 
comparing interventions in real-world studies. Also, some 
of these studies used conventional multivariable regres-
sion models alone to address confounding, but NOAC 
treatments were not prescribed at random in studies that 
analyzed results using multivariable regression. Hence, 
the extraction of adjusted effect estimates is not enough, 
and there could be bias due to selective prescribing influ-
encing the findings. In contrast, propensity score–based 
analytical methods could balance patient characteristics 
and enable a direct comparison of outcomes across the 
different treatment groups and thereby more closely 
emulate the properties of an RCT.10
Such real-world evidence in clinical practice could 
provide a significant platform for the comparative effec-
tiveness and safety of NOACs and aid physicians in deci-
sion-making regarding the choice among NOACs. More 
recently, several studies with improved analytic method-
ologies have been published providing data on the out-
comes of NOAC versus NOAC in real-world settings.11–16 
This meta-analysis was conducted to compare the effec-
tiveness and safety between NOAC and NOAC by only 
including propensity score–based studies.
METHODS
This meta-analysis was conducted according to the guidance 
from the Cochrane Handbook for Systematic Reviews. The 
results of this study were presented according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
directions. We did not obtain ethical approval because only 
the published studies were included. The data that support the 
findings of this meta-analysis would be available from the cor-
responding authors on a reasonable request.
We systematically searched the electronic PubMed and Ovid 
databases until May 2020 to identify all studies comparing the 
effect of one NOAC (dabigatran, rivaroxaban, apixaban, and 
edoxaban) against another in patients with AF (Table I in the 
Data Supplement). Observational studies applied the propensity 
score–based methods (eg, propensity score matching or inverse 
probability of treatment weighting [IPTW]) to balance patient 
characteristics between the two treatment groups. The primary 
effectiveness outcome was stroke or systemic embolism (SSE), 
whereas the primary safety outcome was major bleeding. Our 
secondary effectiveness outcomes included ischemic stroke and 
all-cause death, whereas the secondary safety outcomes were 
intracranial bleeding and gastrointestinal bleeding (Table II in the 
Data Supplement). Data abstraction and quality assessment were 
performed by 2 reviewers independently. The Newcastle-Ottawa 
Scale was used to evaluate the study quality. Hazard ratios (HRs) 
and 95% CIs of the reported outcomes were collected and then 
pooled by a random-effects model complemented with an inverse 
variance heterogeneity or quality effects model.
All the analyses were performed using the Review Manager, 
version 5.3, software (the Cochrane Collaboration 2014, Nordic 
Cochrane Centre Copenhagen, Denmark), the Stata software 
(version 15.0; Stata Corp LP, College Station, TX), and MetaXL 
(version 5.3). Full details of the literature search strategy, inclu-
sion and exclusion criteria, data abstraction, quality assessment, 
and statistical analysis were presented in the Data Supplement.
RESULTS
Study Selection
The flowchart of the literature retrieval of this meta-
analysis is shown in Figure I in the Data Supplement. 
A total of 7220 studies from the electronic databases 
and the reference lists of published reviews were identi-
fied after we removed duplicated publications. In the pro-
cess of the title and abstract screenings, 7189 studies 
were excluded that did not meet the predefined inclu-
sion criteria. And subsequently, 31 remaining studies 
were assessed by the full-text screenings, and 14 stud-
ies were excluded because (1) 7 studies did not apply 
the propensity score–based methods and (2) 7 studies 
used the same data sources (Table III in the Data Sup-
plement). Finally, a total of 17 retrospective cohort stud-
ies11,12,14,16–29 were included in this meta-analysis.
Characteristics of the Included Studies
As presented in Table IV in the Data Supplement, 65% 
of the included studies were derived from nationwide or 
health insurance claims databases in the United States 
(n=11), whereas the rest came from Denmark (n=2), 
China (n=1), Korea (n=1), France (n=1), and Norway 
(n=1). We noted that some studies in the United States 
applied the same data sources, but the different compar-
isons of NOACs or the different outcomes across these 
studies were included for our analysis. For example, Gra-
ham et al and Amin et al extracted the studied populations 
from the Medicare database, but they reported different 
end points of analysis (ischemic stroke, all-cause death, 
Nonstandard Abbreviations and Acronyms
AF atrial fibrillation
HR hazard ratio
IPTW inverse probability of treatment weighting
NOAC  non–vitamin K antagonist oral 
anticoagulant
RCT randomized clinical trial
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intracranial bleeding, and gastrointestinal bleeding in the 
study of Graham et al, whereas SSE and major bleeding 
in the study of Amin et al).
A total of 14 studies11,12,14,17,19–23,25–29 used propen-
sity score matching, and 3 studies16,18,24 used IPTW to 
achieve a balanced distribution of confounders between 
the study groups, respectively. The propensity score–
matched variables of included studies are shown in Table 
V in the Data Supplement. We found that only one study 
by Lee et al18 provided the data on edoxaban compared 
with other NOACs, and thus, the studied comparisons of 
rivaroxaban versus dabigatran, apixaban versus dabiga-
tran, and apixaban versus rivaroxaban were adopted for 
our current meta-analysis.
Patient characteristics between NOAC versus 
NOAC are shown in Table 1. There were no systematic 
differences in the baseline patient characteristics includ-
ing age, the proportion of women, total scores of stroke 
or bleeding risk predictive models, comorbid diseases, 
and medications. For the quality assessment, a total of 4, 
12, and 1 studies had a Newcastle-Ottawa Scale score 
of 8, 7, and 6 points, respectively (Table VI in the Data 
Supplement). Therefore, all the included studies showed 
a moderate to high quality and were acceptable.
Comparative Effectiveness and Safety
Crude event rates of the effectiveness and safety out-
comes of NOACs (dabigatran, rivaroxaban, and apixaban) 
to each other are presented in Table VII in the Data Supple-
ment, whereas the pooled HRs of the studied outcomes 
between NOAC versus NOAC are summarized in Table 2.
Table 1. Baseline Characteristics of the Propensity Score–Matched Patients With Atrial Fibrillation
 
Rivaroxaban vs dabigatran Apixaban vs dabigatran Apixaban vs rivaroxaban
Rivaroxaban Dabigatran P value Apixaban Dabigatran P value Apixaban Rivaroxaban P value
Age, y; mean±SD 71.0±10.8 71.0±10.7 NS 72.0±10.7 71.8±10.6 NS 70.8±10.9 70.9±10.8 NS
Women, % 43.7 43.2 NS 44.4 44.4 NS 43.9 44.5 NS
CHADS2 (mean±SD) 1.96±1.05 1.90±1.09 NS 2.18±1.24 2.19±1.24 NS 2.30±1.30 2.57±1.25 NS
CHA2DS2-VASc (mean±SD) 3.28±1.71 3.23±1.77 NS 3.33±1.69 3.32±1.74 NS 3.43±1.72 3.47±1.68 NS
HAS-BLED (mean±SD) 2.42±1.18 3.67±1.20 NS 2.58±1.20 2.56±1.24 NS 2.74±1.22 2.71±1.21 NS
Comorbid conditions, %
 Hypertension 78.1 75.9 NS 81.8 81.4 NS 81.6 82.3 NS
 Diabetes 29.3 28.9 NS 30.1 30.3 NS 29.9 30.2 NS
 Heart failure 22.1 20.2 NS 22.5 21.0 NS 22.1 22.8 NS
 Hyperlipidemia 42.6 41.4 NS 42.7 41.7 NS 42.2 42.5 NS
 Ischemic heart disease 29.1 29.0 NS 28.9 29.1 NS 31.2 30.9 NS
 Myocardial infarction 3.0 2.9 NS 3.0 2.8 NS 3.3 3.0 NS
 Chronic kidney disease 7.8 7.6 NS 8.5 8.1 NS 8.0 8.0 NS
 History of stroke or TIA 6.7 7.0 NS 6.0 6.1 NS 6.7 6.4 NS
 History of bleeding 4.3 4.7 NS 5.1 4.9 NS 4.3 4.0 NS
 Peripheral artery disease 16.6 15.5 NS 18.3 17.8 NS 20.0 19.7 NS
 Chronic lung disease 15.4 15.4 NS 16.1 16.5 NS 16.2 16.2 NS
Medications, %
 Antiplatelet drugs 13.0 11.7 NS 20.2 19.1 NS 22.0 20.5 NS
 NSAIDS 21.9 19.4 NS 20.8 18.9 NS 21.2 21.6 NS
 Warfarin NA NA NA NA NA NA 12.5 12.5 NS
 Amiodarone or dronedarone 8.4 8.2 NS 9.7 10.7 NS 9.6 10.4 NS
 β-Blockers 63.6 62.8 NS 66.6 66.6 NS 67.0 66.7 NS
 Statins 56.3 55.9 NS 58.4 58.5 NS 57.2 57.5 NS
 ACE inhibitors or ARBs 50.8 49.4 NS 55.5 56.0 NS 46.9 49.3 NS
 Calcium channel blockers 39.3 38.7 NS 41.0 41.2 NS 41.1 41.3 NS
 Digoxin 11.2 11.3 NS 11.1 11.2 NS 11.1 11.3 NS
 Diuretics 20.4 20.4 NS 20.0 19.9 NS 20.1 20.0 NS
 Proton-pump inhibitors 29.0 28.7 NS 29.3 29.2 NS 27.9 28.3 NS
 H2 blockers NA NA NA NA NA NS 5.3 5.3 NS
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; HAS-BLED, hypertension, abnormal liver/renal function, stroke, bleeding history or 
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Primary Outcomes Comparing NOAC Versus 
NOAC
Rivaroxaban Versus Dabigatran
As shown in Figure 1, the use of rivaroxaban com-
pared with dabigatran was significantly associated with 
increased risks of SSE (1.39% versus 1.19%; HR, 1.16 
[95% CI, 1.05–1.29]) and major bleeding (1.99% versus 
1.60%; HR, 1.32 [95% CI, 1.24–1.41]) with no statistical 
heterogeneity (I2=0%).
Apixaban Versus Dabigatran
As presented in Figure 2, there was no significant differ-
ence in SSE (1.15% versus 1.39%; HR, 0.84 [95% CI, 
0.56–1.28]) between the two groups, but apixaban was 
associated with a reduced risk of major bleeding com-
pared with dabigatran (1.34% versus 1.94%; HR, 0.78 
[95% CI, 0.67–0.90]). To examine the source of hetero-
geneity for SSE (I2=85%) and major bleeding (I2=61%), 
we found the study of Amin et al21 was only restricted to 
patients aged ≥65 years. As such, we excluded this study 
and then reperformed the meta-analysis. With this adjust-
ment, the pooled HRs were not significantly changed, but 
the I2 values of SSE and major bleeding were reduced to 
2% and 55%, respectively.
Apixaban Versus Rivaroxaban
As shown in Figure 3, the outcome of SSE was compara-
ble between apixaban versus rivaroxaban (0.98% versus 
1.24%; HR, 0.83 [95% CI, 0.67–1.04]). Compared with 
rivaroxaban use, the use of apixaban was significantly 
associated with a decreased risk of major bleeding 
(1.42% versus 5.07%; HR, 0.63 [95% CI, 0.54–0.73]). 
High heterogeneity was observed for SSE (I2=80%) and 
major bleeding (I2=83%). We excluded the study of Amin 
et al21 that only evaluated the safety and effectiveness 
of NOACs in the elderly and found that the pooled HRs 
were not significantly changed.
Secondary Outcomes Comparing NOAC Versus 
NOAC
As shown in Figures II and III in the Data Supplement, 
the use of rivaroxaban versus dabigatran was signifi-
cantly associated with increased risks of all-cause death 
(HR, 1.24 [95% CI, 1.07–1.45]), intracranial bleeding 
(HR, 1.74 [95% CI, 1.54–1.97]), and gastrointestinal 
bleeding (HR, 1.13 [95% CI, 1.01–1.26]) but yielded 
no difference in ischemic stroke. Compared with dabi-
gatran use, the use of apixaban was associated with 
a reduced risk of gastrointestinal bleeding (HR, 0.60 
[95% CI, 0.48–0.75]) but associated with an increase 
in intracranial bleeding (HR, 1.31 [95% CI, 1.09–1.57]). 
Similar risks of ischemic stroke and all-cause death were 
observed between apixaban versus dabigatran (Figure 
IV in the Data Supplement). Apixaban versus rivaroxa-
ban was associated with decreased risks of intracranial 
bleeding (HR, 0.86 [95% CI, 0.74–0.98]) and gastroin-
testinal bleeding (HR, 0.58 [95% CI, 0.44–0.77]) but had 
a comparable risk of ischemic stroke (Figure V in the 
Data Supplement).
Table 2. Pooled HRs of the Efficacy and Safety Outcomes Between Non–Vitamin K Antagonist Oral Anticoagulant Versus 
Non–Vitamin K Antagonist Oral Anticoagulant in Patients With Atrial Fibrillation






 No. of effect estimates 6 9 5 9 10 10
 Crude event rates 1.39% vs 1.19% 0.82% vs 0.79% 1.06% vs 1.03% 1.99% vs 1.60% 0.35% vs 0.22% 1.40% vs 1.34%
 HRs and 95% CIs 1.16 (1.05–1.29) 0.97 (0.90–1.04) 1.24 (1.07–1.45) 1.32 (1.24–1.41) 1.74 (1.54–1.97) 1.13 (1.01–1.26)
 P value 0.003 0.40 0.006 <0.00001 <0.00001 0.03
 I2 statistic 0% 0% 67% 0% 0% 74%
Apixaban vs dabigatran
 No. of effect estimates 5 5 2 9 6 6
 Crude event rates 1.15% vs 1.39% 0.77% vs 0.79% 0.66% vs 0.82% 1.34% vs 1.94% 0.25% vs 0.24% 0.69% vs 1.40%
 HRs and 95% CIs 0.84 (0.56–1.28) 0.95 (0.82–1.09) 0.92 (0.82–1.03) 0.78 (0.67–0.90) 1.31 (1.09–1.57) 0.60 (0.48–0.75)
 P value 0.43 0.47 0.14 0.0007 0.004 <0.00001
 I2 statistic 85% 47% 0% 61% 17% 84%
Apixaban vs rivaroxaban
 No. of effect estimates 5 4 1 9 5 5
 Crude event rates 0.98% vs 1.24% 0.78% vs 0.87% … 1.42% vs 5.07% 0.29% vs 0.39% 0.77% vs 1.19%
 HRs and 95% CIs 0.83 (0.67–1.04) 0.95 (0.83–1.08) … 0.63 (0.54–0.73) 0.86 (0.74–0.98) 0.58 (0.44–0.77)
 P value 0.11 0.40 … <0.00001 0.03 0.0002
 I2 statistic 80% 63% … 83% 25% 94%
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Sensitivity Analysis and Subgroup Analysis
For the primary outcomes of SSE and major bleeding, 
reanalyses with an inverse variance heterogeneity or 
quality effects model suggested similar results as the 
abovementioned analysis with a random-effects model 
(Figures VI through VIII in the Data Supplement). In the 
sensitivity analysis, the results were consistent with the 
main analysis after we excluded the studies based on 
the method of IPTW (Figures IX through XI in the Data 
Supplement) or only included the studies with a follow-
up of <1 year (Figures XII through XIV in the Data 
Supplement). The results of the subgroup analyses are 
presented in Table 3. There were no significant interac-
tions regarding primary outcomes between NOAC and 
NOAC stratified by age (Figures XV through XVII in the 
Data Supplement). Americans had fewer risks of SSE 
and major bleeding than non-Americans in the groups of 
apixaban versus dabigatran, or apixaban versus rivaroxa-
ban, but not rivaroxaban versus dabigatran (Figures XVIII 
through XX in the Data Supplement).
Publication Bias
For the primary effectiveness and safety outcomes, 
there were seemingly no potential publication biases 
by inspecting the funnel plots (Figure XXI in the Data 
Supplement). In addition, the Egger and Begg tests sug-
gested no publication bias (all P>0.1). For the secondary 
outcomes, there were no publication biases inspected by 
the funnel plots (Figure XXII in the Data Supplement).
DISCUSSION
In the present study, our results based on the data of 
observational studies with proper matching techniques 
and a large sample size indicated the following: (1) when 
compared with dabigatran use, the use of rivaroxaban 
was associated with increased risks of SSE and major 
bleeding; (2) when compared with dabigatran or rivaroxa-
ban, apixaban was found to have a reduced risk of major 
bleeding but a similar risk of SSE; and (3) compared with 
dabigatran or apixaban, rivaroxaban was associated with 
increased risks of intracranial bleeding and gastrointes-
tinal bleeding, whereas the risk of ischemic stroke was 
comparable among the three NOACs.
Current guidelines have recommended NOACs as 
the first choice in the management of nonvalvular AF 
patients.2,4 However, the effectiveness and safety pro-
files among NOACs are undefined because of the lack of 
head-to-head RCTs, leaving physicians with a dilemma in 
Figure 1. Comparing the primary outcomes including stroke or systemic embolism and major bleeding of rivaroxaban with 
dabigatran in patients with atrial fibrillation.
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decisions of initial therapeutic choices. In 2012, Schnee-
weiss et al30 performed the first indirect comparisons 
among NOACs by including 44 535 patients with AF 
enrolled in phase III RCTs for dabigatran, rivaroxaban, and 
apixaban. The authors found no significant differences 
in term of effectiveness outcomes between the NOAC 
groups, whereas apixaban had a better safety profile 
than rivaroxaban or dabigatran.30 In addition, meta-analy-
ses based on the data of observational studies indirectly 
compared one NOAC with another via a common com-
parator, warfarin.31–33 Also, several observational studies 
and meta-analyses provided a significant platform for 
the direct comparative effectiveness and safety profiles 
between NOACs.5,6,9 These indirect and direct compari-
sons consistently observed broadly similar effectiveness 
profiles between NOAC agents but suggested that apix-
aban could be safer for stroke prevention compared with 
dabigatran or rivaroxaban.
Nevertheless, some studies only used conventional 
multivariable logistic or survival regression models to 
address the potential confounders. Pooling data of het-
erogeneous real-world studies without proper matching 
statistical techniques may influence the reliability of their 
findings. Indeed, confounding by indication when compar-
ing NOAC treatments should be considered when inter-
preting the findings of real-world data. Propensity score 
matching and IPTW are increasingly used to reduce con-
founding due to an imbalance in study covariates.
In our current study, all 17 included studies applied 
the methods of propensity score matching or IPTW to 
achieve a balanced patient characteristic between the 
NOAC groups when comparisons are made. Consistent 
with findings of previous meta-analyses,5,6 the results 
of our direct comparisons showed that apixaban pro-
duced less risk of major bleeding than dabigatran or 
rivaroxaban, providing updated evidence in support of 
apixaban for preventing AF-related stroke. Of note, 
Bonde et al13 performed an instrumental variable anal-
ysis of an AF cohort, suggesting that rivaroxaban was 
associated with a higher risk of major bleeding com-
pared with apixaban.
In contrast to previous studies suggesting no statisti-
cally significant efficacy differences among 3 NOACs,5,6 
our study with a large sample size has demonstrated that 
rivaroxaban produced a significantly higher risk of SSE 
than dabigatran. Although Douros et al6 suggested that 
the use of apixaban compared with dabigatran was asso-
ciated with a nonsignificant increased risk of intracranial 
bleeding (HR, 1.27 [95% CI, 0.98–1.63]), our current 
data show that apixaban versus dabigatran was signifi-
cantly associated with an increase in intracranial bleed-
ing (HR, 1.31 [95% CI, 1.09–1.57]).
Figure 2. Comparing the primary outcomes including stroke or systemic embolism and major bleeding of apixaban with 
dabigatran in patients with atrial fibrillation.
IV indicates inverse of the variance.Dow
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Because there are no head-to-head comparisons 
between NOACs, there is no direct evidence to inform 
physicians and patients on the choices among NOACs 
in relation to effectiveness and safety. Our current meta-
analysis utilizing the real-world data was designed to 
directly compare the effectiveness and safety profiles of 
3 individual NOAC drugs in patients with AF. Our results 
strengthen the validity of apixaban superior to dabigatran 
or rivaroxaban for stroke prevention in AF. Real-world 
studies using propensity score–based matching meth-
ods to balance patient characteristics could to some 
degree reduce confounding due to imbalance in study 
covariates. However, the propensity score–based match-
ing methods in previous observational studies still could 
not control for all the unknown or unmeasurable con-
founders, which could have underestimated stroke and 
bleeding risks between NOACs.
Populations in the RCTs are generally selected with 
strict inclusion/exclusion criteria, and whether the results 
of RCTs could be applied to patients in routine care is 
unclear. Real-world studies usually act as a complemen-
tary source of knowledge, and their results are benefi-
cial to validate the RCT findings. If RCTs and real-world 
studies point toward similar findings, they will provide 
robustness evidence supporting the validity of apixaban 
in clinical settings. Until head-to-head RCTs that reflect 
routine use of NOACs are available, our direct compari-
sons based on real-world studies could help clinicians 
in decision-making for the choice of NOACs among 
patients with AF.
Strengths and Limitations
To our best knowledge, this was the first meta-analysis 
using propensity score–based matching techniques to 
balance patient characteristics before a direct compari-
son between NOACs. Another strength of this study was 
that the results of analyses with the inverse variance 
heterogeneity or quality effects models were essentially 
identical to those of primary analysis with the random-
effects model.
Nevertheless, we should acknowledge several limi-
tations of this meta-analysis. First, associations rather 
than causality could be evaluated due to the nature 
of retrospective cohorts included for analysis. Sec-
ond, despite proper adjustments and matching in the 
included studies, potential unmeasured residual con-
founders (eg, race, patient adherence, persistence, and 
duration of NOAC treatments) will still exist at both 
individual trial and meta-analysis levels, which might 
have accounted for the heterogeneity identified for 
some reported outcomes. Third, except for death, no 
Figure 3. Comparing the primary outcomes including stroke or systemic embolism and major bleeding of apixaban with 
rivaroxaban in patients with atrial fibrillation.
IV indicates inverse of the variance.Dow
nloaded from
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other cardiovascular events (eg, myocardial infarction 
and hospitalization) were included in the quantitative 
syntheses of efficacy outcomes because the cor-
responding number of included studies were small. 
Fourth, comparative effectiveness and safety of edoxa-
ban versus other NOACs could not be assessed due to 
the insufficient studies. Finally, the dosage of NOACs 
was not considered in the subgroup analysis due to the 
limiting data. Finally, we could not perform a subgroup 
analysis based on race/ethnic diversity due to the lim-
ited data reported in the included studies.
Conclusions
Current observational comparisons with propensity 
score–based matching methods suggest that apixaban 
might be a better choice compared with dabigatran or 
rivaroxaban for stroke prevention in patients with AF.
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